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Fertility preservation in the young cancer survivor is recognized as a key survivorship issue 
by the American Society of Clinical Oncology and the American Society of Reproductive 
Medicine. Thus, health-care providers should inform women about the effects of 
cancer therapy on fertility and should discuss the different fertility preservation options 
available. It is also recommended to refer women expeditiously to a fertility specialist in 
order to improve counseling. Women’s age, diagnosis, presence of male partner, time 
available, and preferences regarding use of donor sperm influence the selection of the 
appropriate fertility preservation option. Embryo and oocyte cryopreservation are the 
standard techniques used while ovarian tissue cryopreservation is new, yet promising. 
Despite the importance of fertility preservation for cancer survivors’ quality of life, there 
are still communication and financial barriers faced by women who wish to pursue fertility 
preservation.
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iNTRODUCTiON
Cancer in females of reproductive age accounts for nearly 10% of new cancer diagnoses, impacting 
87 per 100,000 women annually (1). The most common cancers presenting in this cohort include 
breast, thyroid, cervical, uterine, melanoma, lymphoma, and colon cancer (Figure 1) (1). Over the 
past four decades, advances in surgery and adjuvant therapy have led to improved 5-year survival 
rates for breast (85.5%), endometrial (91%), cervical (83.2%), and ovarian cancers (79.5%) (2). 
These improved outcomes have resulted in an increased number of cancer survivors in the United 
States, rising from 3 million to nearly 14 million in the past 40 years (1). While improved treatments 
have increased survivorship rates in women with cancer, many therapies are harmful to the ovaries 
and put women at risk of premature ovarian failure and infertility. This is significant as nearly 25% 
of today’s cancer survivors are reproductive-aged woman who may wish to have children. With 
approximately half of women in the United States delaying childbearing into their thirties, the need 
for fertility preservation treatment has never been greater (3).
Fertility is a major concern for women with newly diagnosed cancer (4). A recent survey of 
young women undergoing treatment reported that 51.7% felt that having children was “most 
important” in their life (5). Potential fertility loss is related to emotional distress, fear, anxiety, and 
even moderate or severe depression. These symptoms, especially depression, are more commonly 
FiGURe 1 | Most common cancer in women 15–39 years old. *Incidence rates per 100,000 (1).
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observed in young, non-white, and nulliparous women (6, 7). 
A number of studies suggest the risk of infertility with cancer 
therapy may adversely impact treatment decisions (8, 9). One 
survey evaluating women with early-stage breast cancer demon-
strated that 0.6% of women elected not to receive chemotherapy 
due to fertility risks, whereas 1.9% chose one chemotherapy regi-
men over another to reduce impact on fertility. Similarly, 15.5% 
of women reported rejecting or shortening endocrine therapy 
for fertility reasons (9).
In recent years, an increasing number of female patients with 
cancer have presented to fertility specialists to discuss ways to 
preserve fertility prior to treatment to allow them to become 
biological mothers as cancer survivors (10). The most com-
monly utilized fertility preservation treatments include embryo, 
oocyte, and ovarian tissue cryopreservation (11). Other options 
include adoption or utilization of an egg donor, but studies show 
that the majority of women prefer to have biologically related 
children (10, 12, 13). The American Society of Clinical Oncology 
(ASCO) and the American Society of Reproductive Medicine 
(ASRM) both recognize fertility preservation as a key survivor-
ship issue and recognize fertility preservation treatment as a key 
measure of quality of care (11, 14). Therefore, early referral to a 
fertility specialist and counseling women about their infertility 
risks prior to initiating cancer therapy are essential elements of 
comprehensive cancer care (15, 16). Although fertility preserva-
tion is a well-recognized survivorship issue, many barriers exist 
for women who may choose to pursue fertility preservation 
treatment (4, 17).
The objective of this review is to discuss the impact of cancer 
treatments on fertility in young, female cancer survivors and to 
appraise the fertility preservation treatment options available for 
reproductive-aged women. Additionally, we highlight research 
advancements in the field of fertility preservation and review 
current challenges faced by cancer survivors who may pursue 
fertility preservation treatment.
eFFeCT OF CHeMOTHeRAPY ON 
FUTURe FeRTiLiTY
Females are born with approximately one million oocytes, stored 
as primordial follicles in the ovarian cortex. The number of folli-
cles decreases with increasing age, eventually leading to cessation 
of menses and onset of menopause when their supply is depleted 
(18). However, in women who undergo cancer treatment, this 
process is often accelerated due to the cytotoxic effect of chemo-
therapeutic drugs. These agents primarily affect dividing cells 
and negatively impact follicular maturation. They are directly 
toxic to primordial follicles which may lead to premature ovarian 
failure (19). The risk of premature ovarian failure varies by age, 
chemotherapy agent or combination used, cumulative dose, and 
duration of treatment (18). Girls and young women have a rich 
ovarian reserve. When they undergo chemotherapy, they have a 
lower risk of ovarian failure than older women undergoing the 
same chemotherapy treatment (20). Larsen et al. demonstrated 
that in teenage females undergoing chemotherapy, the risk of 
premature ovarian failure increased by a factor of 4, while for 
women 21–25 years old the risk increased by a factor of 27 (21). 
Regarding the specific chemotherapy agent used (Table 1), alkylat-
ing agents deliver the highest risk of ovarian failure compared to 
other cytotoxic agents. Alkylators alter DNA base pairs, leading 
to cross-links and introducing single-strand DNA breaks (22).
eFFeCT OF RADiOTHeRAPY ON  
FUTURe FeRTiLiTY
The oocyte is extremely sensitive to ionizing radiation, and 
radiation therapy causes a dose- and age-related reduction in 
the ovarian follicular pool (23). The extent of damage depends 
on volume treated, total radiation dose, fractionation technique, 
field arrangement, and patient age (24). Multiple fields are used 
TABLe 1 | Risk of ovarian failure according to the chemotherapeutic 
agent used.
High risk
Alkylating agents
Cyclophosphamide
Ifosfamide
Nitrosoureas
Chlorambucil
Melphalan
Busulfan
Procarbazine
Medium risk
Alkylating agents
Cisplatin
Carboplatin
Doxorubicin
Low or no risk
Alkylating agents
Bleomycin (antibiotic)
Dactinomycin (antibiotic)
Antimetabolite agents
Methotrexate
Mercaptopurine
Fluorouracil
Antimicrotubule agents
Vincristine
Vinblastine
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to minimize radiation-induced toxicity by dividing the exposure 
of normal tissue into multiple different regions. Reproductive 
organs are affected directly, if they are included in the radiation 
field, or indirectly by scattered radiation (24). Current techniques 
such as intensity modulated radiation therapy (IMRT) and image 
guided radiation therapy (IGRT) have been used to maximize the 
dose to tumor and minimize toxicity to surrounding tissue (25).
As with chemotherapy, older females with fewer oocytes 
prior to treatment are most susceptible to ovarian failure (26). 
Additionally, radiation exposure to the uterus may produce tissue 
fibrosis, scarring, and decreased blood supply. This can result in 
infertility as well as poor obstetrical outcomes such as miscar-
riage and preterm birth (27–29). Moreover, brain irradiation can 
damage the hypothalamic–pituitary–gonadal axis, resulting in 
infertility due to anovulation secondary to hypothalamic amen-
orrhea (24).
eFFeCT OF SURGeRY ON FUTURe 
FeRTiLiTY
The diagnosis and initial treatment of gynecological malignan-
cies implies performing surgical procedures to remove the 
affected reproductive organs. Both ovarian and endometrial 
cancers are surgically staged according to the International 
Federation of Gynecology and Obstetrics (FIGO), whereas 
cervical cancer is staged clinically (30, 31). The cornerstone of 
therapy for women with ovarian, fallopian tube, and peritoneal 
cancer is surgical cytoreduction to the presence of no gross 
residual disease, which is associated with increased survival (32). 
Ovarian cancer cytoreduction entails total hysterectomy, bilateral 
salpingo-oophorectomy, pelvic and para-aortic lymph node dis-
section, omentectomy, peritoneal biopsies, and collection of pel-
vic washings (32). Similarly, the standard staging procedure for 
endometrial cancer is total hysterectomy with bilateral salpingo-
oophorectomy (30). Omentectomy is only performed when there 
is serous or clear cell histology. Moreover, pelvic- and para-aortic 
lymphadenopathy is performed selectively depending upon the 
presence of high-grade histology, extend of myometrial invasion, 
and tumor size >2  cm (33). Furthermore, one of the standard 
treatment options for women with early-stage cervical cancer 
(stage IA or IB1) is a hysterectomy (either simple or radical, 
depending on the clinical stage) with pelvic lymphadenectomy 
(34). All of the aforementioned surgical procedures have a direct 
impact on fertility rendering women with cancer infertile or 
menopausal after bilateral removal of the ovaries. Therefore, it 
is necessary to extensively counsel reproductive-aged women 
regarding the risks and benefits of surgical treatment and the 
implications of treatment on fertility. It is also vital to discuss 
more conservative surgical alternatives, if safe, which potentially 
are fertility-preserving.
FeRTiLiTY PReSeRvATiON OPTiONS FOR 
wOMeN PRiOR TO CANCeR TReATMeNT
The ideal fertility preservation treatment should be individual-
ized. It is dependent on the following patient factors: age, diagno-
sis, partner status, preference regarding use of donor sperm, time 
available before treatment, and her desire for future childbearing. 
The primary fertility preservation options today include embryo, 
oocyte, and ovarian tissue cryopreservation. Additional modali-
ties include ovarian transposition and fertility-sparing surgery. 
Table 2 summarizes the fertility preservation treatment modali-
ties detailed below.
embryo Cryopreservation
Embryo cryopreservation is a widely established method for 
preserving reproductive capacity in women. Due to its high 
pregnancy rates, it is considered the “gold standard” fertility 
preservation option offering the best chances of a live birth in the 
future (18). Among women with cancer, one retrospective study 
reported a life birth rate of 44.4% (35).
Embryo cryopreservation requires a woman to undergo an 
in  vitro fertilization (IVF) cycle that involves 10–14  days of 
controlled ovarian hyperstimulation utilizing gonadotropin 
injections. When follicles reach the appropriate size, oocyte 
retrieval is performed via transvaginal ultrasound-guided 
needle aspiration of follicular fluid while the patient is sedated. 
Oocytes are then fertilized in vitro and cryopreserved, typically 
at the blastocyst stage, for future use (18). Most women with a 
male partner choose embryo cryopreservation, whereas some 
women without a male partner may choose this method by 
using donor sperm (24). Studies have shown conflicting results 
regarding the number of eggs harvested from female cancer 
patients compared to those without cancer. In most studies, 
cancer survivors possess a lower, but still adequate, number 
of oocytes when compared to age-matched controls without 
TABLe 2 | Fertility preservation options for young cancer survivors.
Fertility option ideal patient Success rates Benefits Drawbacks
Embryo 
cryopreservation
•	 Has male partner or willing to 
use donor sperm
•	 Has time for ovarian stimulation 
prior to treatment
•	 Cumulative pregnancy rate of 66% 
among women with cancer
•	 Standard technique
•	 Predictable likelihood of 
success
•	 Financially costly
•	 Requires time to stimulate 
ovaries to retrieve eggs
Oocyte 
cryopreservation
•	 Postpubertal women without 
a male partner or who do not 
wish to use donor sperm
•	 Pregnancy rate per cycle of 50.2% 
or per embryo-transfer 55.4%
•	 Standard technique
•	 For women with ethical or 
religious objections to embryo 
•	 For women in countries where 
embryo cryopreservation is 
prohibited freezing
•	 Greater reproductive flexibility
•	 Financially costly
•	 Requires time to stimulate 
ovaries to retrieve eggs
Ovarian tissue 
cryopreservation
•	 Prepubertal girls or young 
women who do not have 
time for ovarian stimulation to 
retrieve eggs
•	 Pregnancy rate of 25% among 
women with cancer
•	 Experimental
•	 No delay in the initiation of 
cancer therapy
•	 Male partner and ovarian 
stimulation are not required
•	 Requires surgical procedure to 
harvest tissue
•	 Ovarian tissue could potentially 
be seeded with malignant cells
Ovarian 
transposition
•	 Females with planned pelvic 
radiation therapy
•	 Success rate (preservation of short-
term menstrual function) varies from 
16 to 90%
•	 Ideal for patient requiring local 
pelvic radiation
•	 Requires surgical procedure
Fertility sparing 
surgery
•	 Women with certain early-stage 
gynecological malignancies
•	 Cumulative conception rate after 
trachelectomy 53%
•	 Ovaries and/or uterus are 
preserved
•	 Pregnancy rate after progestin 
therapy for endometrial cancer 34.8%
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cancer (36–39). Of note, however, Oktay et  al. demonstrated 
that women with the BRCA1 mutation appear to have a sig-
nificantly lower ovarian response and produce fewer eggs per 
ovarian stimulation cycle (7.4 vs. 12.4) than women without the 
mutation (40).
The primary drawbacks to IVF include the time required, cost, 
and risk of ovarian hyperstimulation syndrome (OHSS) (6, 24). 
Medical expenses for an IVF cycle for fertility preservation are 
often not covered by private- or government-based insurance 
(41). The standard controlled ovarian hyperstimulation protocol 
starts at the onset of menses, which could result in a delay of 
2–4 weeks (42, 43). While the conventional ovarian stimulation 
protocol is initiated at the beginning of the follicular phase, “ran-
dom start” protocols may be initiated at the late follicular, perio-
vulatory, or luteal phase (18). The latter protocols have similar 
numbers of oocytes retrieved, oocyte maturity, and fertilization 
rates than conventional-start protocols (44). Thus, random start 
protocols have proven to decrease total time to starting the IVF 
cycle, and cancer treatment, without compromising oocyte or 
embryo yield (44–47). An important risk to women undergoing 
IVF cycles is OHSS. Severe OHSS is a rare but serious complica-
tion of controlled ovarian stimulation. Women with OHSS may 
present with lower abdominal discomfort, nausea, vomiting, 
abdominal distension, ovarian enlargement, and ascites due 
to increased vascular permeability and third-spacing of fluid. 
Serious complications can include venous thromboembolism 
and stroke. Fortunately, there are techniques available to help 
prevent this iatrogenic condition, which may contribute to a 
delay in initiating cancer therapy (48).
Oocyte Cryopreservation
Oocyte cryopreservation is a fertility preservation treatment 
most suitable for single or adolescent women. It is often chosen 
by women without partners or by those with a partner who desire 
maximum reproductive flexibility. Oocyte cryopreservation is 
also an option for women with religious or ethical objections to 
embryo freezing (14, 18). This fertility preservation modality was 
considered experimental until 2013. At that time, the Practice 
Committees of ASRM and the Society for Assisted Reproductive 
Technology (SART) concluded that mature oocyte cryopreserva-
tion should no longer be considered experimental. Therefore, 
they recommended this strategy for patients facing infertility due 
to chemotherapy or other gonadotoxic therapies when embryo 
cryopreservation is not possible (49).
Major drawbacks of oocyte cryopreservation include the time 
needed for ovarian stimulation as well as its decreased efficiency 
compared to embryo cryopreservation. Oocyte cryopreserva-
tion is technically more difficult than embryo cryopreservation 
due to the oocyte’s increased water content, making it more 
prone to cryoinjury. An egg’s meiotic spindle, cytoskeleton, and 
cortical granules are sensitive to damage by ice crystals during 
freezing and thawing (50). Also, hardening of the zona pellucida 
after  cryopreservation hinders fertilization (51). However, in 
recent years, there have been remarkable advances in oocyte 
cryopreservation techniques, which have allowed 70–90% of 
cryopreserved oocytes to survive the freeze-thaw process (52, 53). 
Intracytoplasmic sperm injection (ICSI), in which a sperm is 
directly injected into a mature egg, allows fertilization despite 
zona pellucida hardening (54).
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Slow-freezing and vitrification are the two primary 
cryopreservation techniques. Vitrification leads to an ultra-rapid 
freezing of cells or tissues by direct contact with liquid nitrogen 
without ice crystal formation. Vitrification has quickly evolved 
to become the most widely used method of egg cryopreservation 
due to the improved oocyte survival (85 vs. 65%) and fertilization 
rates (79 vs. 74%), compared to the slow-freeze method (55, 56). 
Conversely, the slow-freeze method involves use of a cryopro-
tectant that permeates and dehydrates the cell as it is slowly 
cooled, minimizing the intracellular ice crystal formation. After 
cryopreservation, when the woman is ready to pursue childbear-
ing, the oocytes are thawed and fertilized in vitro. The patient can 
then undergo transcervical embryo transfer into the uterus, with 
excess embryos cryopreserved for future use.
In vitro fertilization outcomes with cryopreserved oocytes are 
comparable to fresh IVF and ICSI rates (57). One retrospective 
study showed that oocyte cryopreservation/thaw cycles had no 
significant difference in live-birth rate per mature oocyte retrieved 
when compared to fresh IVF cycles (2.7 vs. 4.2%, respectively) 
(58). Furthermore, randomized trials performed in infertile cou-
ples with supernumerary oocytes and donor oocyte populations 
also reported no significant differences in fertilization rate (88.3 
vs. 84.9%) and clinical pregnancy rate per cycle (50.2 vs. 49.8%) 
between fresh and vitrified oocytes (59, 60).
Special Considerations for embryo or 
Oocyte Cryopreservation in Female 
Cancer Survivors
For women with estrogen-sensitive tumors (i.e., endometrial 
or estrogen receptor positive breast cancer), alternative ovarian 
stimulation protocols have been developed to circumvent the 
theoretical risk of supraphysiologic estradiol levels on cancer 
growth. Selective estrogen receptor modulators (tamoxifen) or 
aromatase inhibitors (letrozole) have been utilized for this pur-
pose (42, 43). In such protocols, letrozole is used in addition to 
the standard gonadotropin dosing. Letrozole, most commonly 
used today, minimizes a women’s serum estradiol level dur-
ing controlled ovarian hyperstimulation. Published reports 
demonstrate a similar number of total oocytes retrieved, length 
of ovarian stimulation, and fertilization rate when compared 
with protocols without letrozole (43, 44, 61). A prospective 
study of 79 women with breast cancer who underwent ovarian 
stimulation using letrozole plus gonadotropins or gonadotro-
pins alone for oocyte/embryo cryopreservation demonstrated 
a recurrence rate and survival that was similar at 2- to 3-year 
follow-up to those who underwent no fertility-preserving 
procedure (62).
Ovarian Tissue Cryopreservation
Ovarian tissue cryopreservation involves harvesting and freezing 
ovarian tissue, allowing preservation of oocytes within primor-
dial follicles located in the ovarian cortex. In the future, the tissue 
can be autotransplanted into the cancer survivor or immature 
oocytes could be harvested and matured in  vitro (18). Major 
benefits of ovarian tissue cryopreservation include that it can 
be performed in prepubertal females, it eliminates the need for 
sperm donation, and it can be performed immediately without a 
cancer treatment delay. Of note, it is the only fertility preserva-
tion option available for prepubertal girls. Moreover, tissue can 
be obtained quickly, and there is potential to have more oocytes 
available for future fertility treatment than can be retrieved from 
a single IVF stimulation (18, 63, 64). This procedure entails ovar-
ian tissue harvesting prior to cryopreservation. Ovarian tissue is 
either harvested laparoscopically or at the time of a laparotomy 
under general anesthesia, regardless of menstrual cycle phase. 
Since many young girls undergo chemotherapy port placement 
under general anesthesia, laparoscopic ovarian tissue harvesting 
can be piggy-backed to this procedure. Due to the location of the 
oocyte-containing follicles in the outer millimeter of the ovary, 
cryopreservation can be limited to only a cortical strip of tissue. 
After cancer treatment, the ovarian cortex tissue is thawed and 
transplanted either orthotopically to remaining ovarian tissue or 
pelvic peritoneum, or it can be transplanted heterotopically to the 
forearm, abdominal wall, or chest wall (18, 65).
Ovarian cryopreservation should ideally be performed 
before the initiation of gonadotoxic therapy since certain 
chemotherapies can significantly decrease ovarian reserve 
with each cycle. A prospective study of women that under-
went ovarian tissue cryopreservation compared the ovarian 
reserve of those who had received chemotherapy (ranged 
from one to seven cycles) with those who had not, with the 
aim of quantifying the effects of alkylating and non-alkylating 
agents on ovarian infrastructure. The authors demonstrated a 
significantly lower primordial follicle counts in women who 
received chemotherapy compared to controls. This effect was 
accentuated when women were treated with alkylating agents 
compared to those patients who did not receive these agents or 
did not receive chemotherapy (66).
Cryopreservation of ovarian tissue is a new, yet promis-
ing, fertility preservation treatment. The first live birth after 
 autotransplantation of human ovarian tissue was reported in 
2004 (67). To date, there have been at least 60 live births after 
ovarian tissue reimplantation (68). The slow-freezing cryopreser-
vation technique was used in the majority of these cases while 
only two used vitrification. In a series of 80 cases from 4 fertility 
centers, the pregnancy rate was of 25.0%. Of note, two women 
each delivered three babies, reflecting potential long-term effi-
cacy of ovarian cryopreservation (68, 69). Ideal candidates for 
this  fertility preservation modality are girls/women under age 35 
with at least a 50% risk of ovarian failure after cancer therapy (70).
Ovarian Transposition
Ovarian transposition, or oophoropexy, is a strategy that can be 
offered to women with planned pelvic radiation. It is commonly 
considered for young women with locally advanced cervical 
cancer. This surgical procedure involves moving one (most 
commonly) or both ovaries out of the pelvis and away from the 
radiation field by laparoscopy or laparotomy (71). The ovary can 
be transposed to the lateral abdominal wall along the ipsilateral 
paracolic gutter, or with ligation to the uterosacral ligament for 
midpelvic or abdominal radiation, respectively (18). In all ovar-
ian transposition cases, marking the boundaries of the ovary with 
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surgical clips will help to identify the ovaries during radiotherapy 
mapping (18). This technique is commonly done unilaterally 
but a combined approach with cryopreservation of one ovary 
and transposition of the other can be also implemented (72). In 
the case of post-treatment failure of the non-transposed ovary, 
oocyte retrieval from the transposed ovary can be performed 
transabdominally if the ovary is not repositioned (18). The overall 
success rate as judged by preservation of short-term menstrual 
function is approximately 50%, although there is a wide variation 
in the reported success rates ranging from 16 to 90% (14, 73). 
Failure of this method is due to scatter radiation, compromise 
of the transposed ovary blood supply, patient age, radiation 
dose, whether the ovaries are shielded during the radiation 
procedure and whether concomitant chemotherapy is used (73). 
Complications related to ovarian transposition include infarction 
of the fallopian tubes and chronic pelvic pain (73, 74).
Fertility-Sparing Surgery
Conservative surgical and medical techniques have been 
increasingly used for the management of early-stage gynecologic 
malignancies, given the impact of fertility preservation on qual-
ity of life (75). Fertility-sparing surgery entails the preservation 
of at least a portion of one ovary and the uterus, and it is more 
commonly offered to women with borderline ovarian tumors, 
non-epithelial ovarian cancers, early-stage cervical cancers, and 
select women with grade 1 endometrioid adenocarcinoma of the 
endometrium (75). Women with an apparent unilateral stage I 
borderline ovarian tumor or low grade ovarian malignancies 
who desire future fertility can be managed in some cases with a 
unilateral salpingo-oophorectomy, omental and peritoneal biop-
sies, and collection of pelvic washings rather than full staging 
for ovarian cancer (76). However, the National Comprehensive 
Cancer Network (NCCN) suggests consideration of completion 
surgery upon meeting childbearing goals for women with a 
remaining ovary (77).
There is limited data about the use of fertility-sparing surgery 
in women with early-stage epithelial ovarian cancer. In a large 
retrospective study of 240 women with epithelial ovarian cancer 
confined to the ovaries who underwent fertility-sparing surgery, 
11.3% of the women relapsed and 4.6% died of progressive dis-
ease after a median follow-up of 9 years. The authors proposed a 
conservative approach (cystectomy or unilateral oophorectomy, 
omentectomy, pelvic washings, at least eight peritoneal biopsies, 
endometrial biopsy, and evaluation of pelvic and para-aortic 
lymph nodes) for appropriately selected young women with 
cancer. However, they recommended careful monitoring of 
women with grade 3 disease given the higher risk of distant 
recurrence (78).
Fertility-sparing surgery is particularly relevant for women 
with cervical cancer, given that this disease presents in women of 
reproductive age. Thus, women with tumors ≤2 cm and without 
evidence of obvious lymph node metastases can undergo cervi-
cal conization or radical trachelectomy, depending on disease 
stage, rather than radical hysterectomy (77). Conization is 
recommended for women with stage IA1 disease and without 
lymphovascular space invasion (79). A study of women 40 years 
or younger with stage IA1 disease using the Surveillance, 
Epidemiology, and End Results (SEER) database found no 
significant difference in 5-year survival between cervical coniza-
tion and hysterectomy (80). Conversely, radical trachelectomy 
is recommended for women with stage IA1 disease with lym-
phovascular space invasion or stage IB1 disease (81). After the 
latter procedure, a 52.8% 5-year cumulative conception rate has 
been reported while reported preterm birth rate is in the range 
of 48–60% (81, 82). Several ongoing prospective trials, including 
a phase 2 trial at MD Anderson Cancer Center (NCT01048853), 
are underway to examine the safety of performing pelvic lym-
phadenectomy with cervical conization or simple hysterectomy 
for cervical cancer treatment. This study has an estimated enroll-
ment of 100 participants and includes women with squamous cell 
carcinoma, FIGO stage IA2 or IB1, tumor diameter ≤2 cm, no 
lymphovascular space invasion on biopsy or cone and <10 mm 
of cervical stromal invasion (83).
In the case of uterine cancer, women with grade 1 or 2 endo-
metrioid cancer confined to the endometrium may be candidates 
for progestin therapy such as megestrol acetate and deferral of 
surgical staging until after completion of childbearing. These 
women should have a dilation and curettage and imaging stud-
ies performed before medical therapy with the aim of excluding 
high-grade disease or advanced stages (84). A systematic review 
by Gunderson et  al. of women treated with progestin therapy 
for grade 1 endometrioid carcinoma demonstrated a complete 
response rate of 48.2%. The time to complete response, which 
included women with hyperplasia, varied from 1 to 18 months 
(median 6  months). Moreover, the pregnancy rate for women 
with a history of carcinoma was 34.8% (84).
COUNSeLiNG AND ReFeRRAL OF 
wOMeN iNTeReSTeD iN FeRTiLiTY 
PReSeRvATiON
It is well established that health-care providers should convey 
information about fertility risks and fertility preservation treat-
ment to their patients as part of a comprehensive treatment plan. 
Open-ended dialog should include discussion of key points such 
as scientific data, advantages and disadvantages, anticipating 
delay of childbearing, patient preferences, and reproductive 
potential (11). Moreover, in order to improve information shar-
ing, it is also beneficial to provide women with written material 
before and after counseling (16).
According to the ASCO Clinical Practice Guidelines, health-
care providers should discuss with women interested in fertility 
preservation several key issues (11). The first key point is to 
discuss the feasibility of pursuing fertility preservation options 
depending on each patient’s recurrence risk and prognosis. 
Then providers should inform women of their individual risks 
of infertility or early menopause from oncologic therapy, taking 
into account individual factors. Patients should be told whether 
their treatment would place them in high, medium, low or 
non-existent risk. Next, fertility preservation treatment options, 
including those considered experimental, should be reviewed 
with their respective success rates. Health-care providers should 
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communicate to women regarding the limited data available on 
oocyte cryopreservation and its decreased efficacy compared 
to embryo cryopreservation. It should be explained that these 
procedures may be subject to time constraints and treatment 
may be delayed. Patients should be informed that insurance cov-
erage is improving for fertility preservation, and they should be 
encouraged to consult with their insurance companies. Providers 
should explain that even though there is a paucity of data, there 
appears to be no increased risk of cancer recurrence from fertility 
preservation interventions or pregnancy. Finally, an expeditious 
referral should be made to a fertility specialist for more infor-
mation. Meeting with a social worker may also be beneficial for 
assessment of distress and to suggest advocacy organizations, 
which may provide financial resources.
BARRieRS TO PURSUiNG FeRTiLiTY 
PReSeRvATiON
Fertility preservation is of paramount importance for the qual-
ity of life of cancer survivors. Yet, this topic is not consistently 
addressed in clinical practice despite the aforementioned ASCO 
recommendations (14, 85). Moreover, there are still many factors 
that impact patients’ access to fertility preservation options. For 
example, both health staff and patients have their own concerns 
when it comes to discussing the effects that cancer therapy has on 
fertility. Although qualitative, a study reported that health-care 
providers voluntarily avoid this subject due to their beliefs that 
fertility in cancers such as Hodgkin’s lymphoma would not be 
affected by first-line chemotherapy and that fertility preservation 
treatments are not effective. Additionally, fertility preservation 
discussion may be avoided due to the sense of urgency in provid-
ing cancer care without delay (4).
Conversely, there are a number of reasons why young women 
may refrain from discussing the topic with health-care provid-
ers, such as being overwhelmed with their cancer diagnosis or 
unaware of the consequences that cancer treatment may have on 
their fertility. They often fear that delaying cancer treatment to 
pursue fertility preservation may negatively impact their survival 
(11, 86). These concerns reflect communication and information 
barriers, which can be addressed with education to both health-
care providers and patients. Thus, it is important to inform 
patients that there is no significant delay in cancer treatment 
when pursuing fertility preservation options and that a prompt 
referral to a fertility specialist optimizes the lag time between 
diagnosis and start of cancer treatment (87, 88). A retrospective 
study demonstrated no difference in time from initial diagnosis 
to chemotherapy in women that underwent oocyte retrieval vs. 
women who did not (71 vs. 67 days, respectively, p < 0.27) (87). 
Likewise, another observational study of breast cancer patients 
showed that women referred to a subspecialist before surgery had 
a shorter time interval from initial diagnosis to initiation of ovar-
ian stimulation (42.6 vs. 71.9 ± 30.7 days; p < 0.001, respectively) 
and to initiation of chemotherapy (83.9 vs. 107.8 days; p = 0.045) 
than women referred after surgery. Early referral can also allow 
repeated stimulation cycles, resulting in a larger number of oocytes 
or embryos for cryopreservation prior to cancer  treatment (88).
Several studies have reported that up to 50% of young female 
cancer survivors did not receive sufficient education regarding 
fertility preservation options (89, 90). Furthermore, a population-
based study demonstrated that only 56.3% of adolescent and 
young adults with cancer recalled discussing fertility preserva-
tion options and only 6.8% reported making arrangements to 
pursue any of those options. The authors also described that 
those discussions were less likely to occur if women were raising 
children or if they lacked private insurance. Additionally, 38% 
of the women reported not making arrangements for fertility 
preservation because they were unaware of the options, whereas 
19% reported having cost issues. Strikingly, the study showed 
that men with cancer were more than twice as likely as women 
to report discussion of fertility preservation options and to make 
arrangements for fertility preservation (85). The sex differences 
found in these and other studies may be related to the costs and 
complexity of female fertility preservation options and to the fact 
that oocyte cryopreservation was experimental when women in 
the study were initially diagnosed (4, 85).
In addition to unmet communication needs, financial expenses 
are one of the most relevant barriers that cancer survivors face 
when making a decision about their reproductive future. The 
current costs of ovarian stimulation drugs ($2000–$5000), egg 
harvesting ($5000–$8000), annual storage ($500–$1000/year), 
and each attempt at embryo transfer ($4000–$5000) make it chal-
lenging to cover these expenses out-of-pocket (41). Unfortunately, 
insurance does not cover fertility preservation treatment for most 
female patients. The laws and regulations that address insurance 
coverage for fertility treatment define infertility as an inability to 
conceive after 1 year of regular and unprotected intercourse and 
do not mention the infertility caused by cancer therapy. Thus, 
there are no codified insurance mandates that would cover the 
expenses for fertility treatment specifically of cancer survivors 
(41). Moreover, as the laws pertaining to insurance coverage for 
infertility and IVF procedures vary among and within states, the 
obstacles that the survivors encounter when attempting to assess 
these services also vary widely (41). Conversely, due to the experi-
mental nature of ovarian tissue cryopreservation, health insurers 
are not required to cover this service. This therefore limits the 
options for fertility preservation for prepubertal girls and young 
women (41).
Rationale behind the lack of insurance coverage for assisted 
reproductive technology in cancer patients are related to the view 
of these procedures as elective and not medically necessary (91). 
Fortunately, in recent years, there has been a slight increase in 
insurers covering fertility preservation treatment on a case-by-
case basis. This highlights the importance of advising patients to 
contact their insurance companies regarding insurance coverage. 
Patients should also be encouraged to reach out to non-profit 
organizations that provide women with financial assistance for 
preservation treatment (92).
CONCLUSiON
Fertility preservation has become a significant aspect of 
comprehensive cancer care (24). The idea of not having a 
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child of her own is a key source of distress in women with 
cancer undergoing gonadotoxic therapy. Health-care provid-
ers should discuss with women about their fertility wishes 
and counsel them regarding fertility preservation treatment 
options. Moreover, determining the need and best technique 
for fertility preservation requires an individualized assessment 
that is best performed by a fertility specialist. Barriers to fertil-
ity preservation counseling and receiving treatment continue 
to exist.
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